Iron Metabolism in Thalassemia and Sickle Cell Disease

被引:0
|
作者
Mariani, Raffaella [1 ,2 ]
Trombini, Paola [1 ,2 ]
Pozzi, Matteo [1 ,2 ]
Piperno, Alberto [1 ,2 ]
机构
[1] Univ Milano Bicocca, Dept Clin Med & Prevent, Milan, Italy
[2] SGerardo Hosp, Ctr Diag & Treatment Hemochromatosis, Monza, Italy
关键词
D O I
10.4084/MMID.2009.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There are two main mechanisms by which iron overload develops in thalassemias: increased iron absorption due to ineffective erythropoiesis and blood transfusions. In nontransfused patients with severe thalassemia, abnormal dietary iron absorption increases body iron burden between 2 and 5 g per year. If regular transfusions are required, this doubles the rate of iron accumulation leading to earlier massive iron overload and iron related damage. Iron metabolism largely differs between thalassemias and sickle cell disease, but chronic transfusion therapy partially normalize many of the disparities between the diseases, making iron overload an important issue to be considered in the management of patients with sickle cell disease too. The present review summarizes the actual knowledge on the regulatory pathways of iron homeostasis. In particular, the data presented indicate the inextricably link between erythropoiesis and iron metabolism and the key role of hepcidin in coordinating iron procurement according to erythropoietic requirement. The role of erythropoietin, hypoxia, erythroid-dependent soluble factors and iron in regulating hepcidin transcription are discussed as well as differences and similarities in iron homeostasis between thalassemia syndromes and sickle cell disease.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia
    Ellen, B. Fung
    Harmatz, Paul R.
    Milet, Meredith
    Coates, Thomas D.
    Thompson, Alexis A.
    Ranalli, Mark
    Mignaca, Robert
    Scher, Charles
    Giardina, Patricia
    Robertson, Shanda
    Neumayr, Lynne
    Vichinsky, Elliott P.
    BONE, 2008, 43 (01) : 162 - 168
  • [22] Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease
    Ghugre, Nilesh R.
    Gonzalez-Gomez, Ignacio
    Butensky, Ellen
    Noetzli, Leila
    Fischer, Roland
    Williams, Roger
    Harmatz, Paul
    Coates, Thomas D.
    Wood, John C.
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (08) : 480 - 483
  • [23] Immunological Inhibition Arising From Misplaced Iron: Implications for Thalassemia and Sickle Cell Disease
    Mustafa, I.
    Scott, M.
    TRANSFUSION, 2009, 49 : 32A - 33A
  • [24] Progression of organ dysfunction in iron overloaded patients with β thalassemia and sickle cell disease.
    Fung, EB
    Harmatz, P
    Madden, J
    Vichinsky, E
    BLOOD, 2004, 104 (11) : 468A - 468A
  • [25] Milestones in the history of thalassemia and sickle cell disease
    Loukopoulos, Dimitris
    THALASSEMIA REPORTS, 2014, 4 (03) : 29 - 32
  • [26] SICKLE CELL-THALASSEMIA DISEASE IN JAMAICA
    MACIVER, JE
    WENT, LN
    CRUICKSHANK, EK
    BLOOD, 1958, 13 (04) : 359 - 366
  • [27] Newborn Screening for Sickle Cell Disease and Thalassemia
    Quarmyne, Maa-Ohui
    Bock, Fiona
    Lakshmanan, Sangeetha
    Attell, Brandon K.
    Snyder, Angela
    Boudreaux, Jeanne
    Sheth, Sujit
    Bender, M. A.
    Lal, Ashutosh
    JAMA HEALTH FORUM, 2025, 6 (03):
  • [28] Clinical Features of β-Thalassemia and Sickle Cell Disease
    McGann, Patrick T.
    Nero, Alecia C.
    Ware, Russell E.
    GENE AND CELL THERAPIES FOR BETA-GLOBINOPATHIES, 2017, 1013 : 1 - 26
  • [29] Gene therapy for sickle cell disease and thalassemia
    Scaramellini, Natalia
    Panzieri, Daniele Lello
    Cappellini, Maria Domenica
    CURRENT OPINION IN HEMATOLOGY, 2025, 32 (03) : 120 - 129
  • [30] SICKLE-CELL THALASSEMIA DISEASE IN TANZANIA
    KIMATI, VP
    MASSAWE, AW
    LEMA, RA
    MAGESA, PM
    ARUNKUMAR, BK
    EAST AFRICAN MEDICAL JOURNAL, 1980, 57 (12) : 861 - 866